An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function

Trial Profile

An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2015

At a glance

  • Drugs Fedratinib (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2013 Actual initiation date changed from 1 Dec 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov record.
    • 23 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top